Story thread · 3 reports / 3 sources
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharmadive.com · 4d
How the coverage leans
Across 3 sources · syndicated copies counted once
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
First report: A New Gene Editing Technique May Reduce Some CRISPR Risks, But Raises Ethical Concerns — discovermagazine.com, 7d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.